Medtronic, Boston Scientific ink patent accord
This article was originally published in The Gray Sheet
Executive Summary
Firms settle two patent suits and agree to stand down in three others, ending all current litigation between the companies related to interventional cardiology and endovascular repair technology intellectual property, the companies announce Jan. 27. The two settled cases and one of the discontinued cases were pending in the U.S. District Court for the Eastern District of Texas. The other two discontinued cases were filed in the U.S. District Court for the Northern District of California. While terms of the settlement were not disclosed, Boston Scientfic notes that the agreement will have no material impact on its financial results